Crossmark

Comparative efficacy and safety of irreversible (rasagiline) and reversible (safinamide) monoamine oxidase inhibitors as add-on therapy for Parkinson’s disease

Crossref DOI link: https://doi.org/10.1007/s00415-025-13230-w

Published Online: 2025-07-01

Published Print: 2025-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Khalid, Marwah Bintay

Shahzad, Faizan

Siddiqui, Momina Riaz

Abedin, Muhammad Zain Ul

Hulou, Saad

Shami, Besher https://orcid.org/0009-0002-0685-8991
Ahmed, Syed Ijlal
License Information

Text and Data Mining valid from 2025-07-01

Version of Record valid from 2025-07-01
More Information

Article History

Received: 26 May 2025

Revised: 24 June 2025

Accepted: 24 June 2025

First Online: 1 July 2025

Declarations

:

: The authors would like to declare no conflicts of interest.

: Since this is a review article, ethical approval is not required.

: Since this is a review article of already published data, informed consent is waived.

Document is current

Any future updates will be listed below